TORONTO, Dec. 04, 2023 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) EDT, a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update for the month of November on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Dr. John Kellum, Chief Medical Officer of Spectral, commented, “In November we experienced strong enrollment into Tigris despite the U.S. Thanksgiving holiday, with five patient enrollments in the last six weeks. We continue to make progress opening additional sites, which should positively impact the pace of enrollment. Additionally, the high rates of influenza…
